✦ LIBER ✦

41-5 - Transdermal delivery of xanomeline, and M1/M4 agonist in development for the treatment of Alzheimer's disease

✍ Scribed by N.C. Bodick; R. Lucas; J.H. Satterwhite; W.W. Offen

Book ID: 118511876
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 429 KB
Volume: 42
Category: Article
ISSN: 0006-3223
DOI: 10.1016/s0006-3223(97)87420-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Xanomeline, a potent and specific M1 ago

Xanomeline, a potent and specific M1 agonist in the treatment of mild and moderate Alzheimer's disease

✍ Pretzsch, Hans 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 123 KB

SAT-5-2 The discovery and pharmacology o

SAT-5-2 The discovery and pharmacology of xanomeline, a muscarinic M1 receptor agonist for Alzheimer's disease

✍ H.E. Shannon; E.P. Bymaster; D.O. Calligaro; N.W. DeLapp; C.H. Mitch; J.S. Warc; 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 138 KB

O-20-4 - The M1 muscarinic agonist xanom

O-20-4 - The M1 muscarinic agonist xanomeline improves both cognitive and behavioral deficits in Alzheimer's disease

✍ N. Bodick; W. Offen 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 151 KB

SAT-5-3 Xanomeline in mild and moderate

SAT-5-3 Xanomeline in mild and moderate Alzheimer's disease; the effects of a novel M1 agonist on behavior

✍ Neil C. Bodick; Walter Offen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 278 KB

Xanomeline: A selective muscarinic agoni

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

✍ Frank P. Bymaster; Celia A. Whitesitt; Harlan E. Shannon; Neil DeLapp; John S. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 3 views

Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected

S-16-4 Xanomeline: The first study of th

S-16-4 Xanomeline: The first study of the safety and efficacy of an M1 agonist in mild and moderate Alzheimer's disease

✍ Neil C. Bodick; Walter Offen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 143 KB